NCT02443935View on ClinicalTrials.gov

Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 1, 2017

Study Completion Date

June 25, 2017

Conditions
HIV
Interventions
DRUG

MGN1703

60 mg s.c. twice weekly for 4 weeks

DRUG

MGN1703

60 mg s.c. twice weekly for 24 weeks

Trial Locations (2)

2650

Department for Infectious Diseases, Amager and Hvidovre Hospitals, Hvidovre

8200

Department for Infectious Diseases, Aarhus University Hospital, Aarhus N

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT02443935 - Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection | Biotech Hunter | Biotech Hunter